Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $2.19, $0.07 better than the analyst estimate of $2.12. Revenue for the quarter came in at $385.2 million versus the consensus estimate of $437.93 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.